Skip to main content
. 2022 Dec 13;10(12):2129. doi: 10.3390/vaccines10122129

Figure 2.

Figure 2

SARS-CoV-2 spike-specific immunoglobulin G (IgG) and neutralizing responses against the wild type and omicron variants of SARS-CoV-2 at median 63 days after a third COVID-19 vaccination in people living with HIV (PLWH) and healthcare workers (HCWs). (A) SARS-CoV-2 spike-specific IgG, (B) neutralizing responses against wild type and omicron variant, (C) neutralizing responses against the omicron variant after a third homologous mRNA vaccination, (D) neutralizing responses against the omicron variant in homologous and heterologous vaccinated PLWH, and (E) neutralizing responses against the omicron variant according to days after the third vaccination in PLWH.